The present study suggests an intriguing possibility of using endothelin-1 and oxytocin, as well as their therapeutic analogs, as novel therapeutic targets for memory loss, such as that seen in Alzheimer's disease. The gene discussed is EDN1; the disease is early-onset autosomal dominant Alzheimer disease.